How to best standardise imaging result from multi centre clinical trials
SMi present their 8th annual conference on.........
Imaging in Cancer Drug Development
14-15 March 2012, Copthorne Tara Hotel, London
/EINPresswire.com/ The number of patients diagnosed with cancer worldwide each year is estimated to be 12.5 million. The need for new therapeutics has never been greater. Currently, the process of drug discovery and taking a potential product through the developmental stages is a long and costly one. Taking almost 12 years and costly approximately $800 million. Pharmaceutical and research companies are looking for new ways to save costs and time. With advancements in imaging technology these companies are being given greater opportunity for translational approaches to drug development. With these opportunities companies also face challenges such as what techniques are most suited to the pathway they are trying to model? Can these models justify translation into human subjects?
Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.
Hear from industry experts on the current applications of imaging in all stages of drug design, in depth verity of imaging modalities and how they can be best applied in the drug development process. Find out how to use imaging techniques to reduce the long term cost of drug development and case studies discussions on how to best standardise imaging result from multi centre clinical trials.
Leading speakers include:
• Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
• Yanping Luo, Group Leader Translational Imaging, Abbott
• Peter Eggelton, Medical Director Oncology, Merck
• Paul McSheehy, Director Oncology, Novartis
• Anthony M Giamis, Head of Radiochemistry, Abbott
• Christopher Foley, Imaging Manager, GlaxoSmithKline
• Simon Walker-Samuel, Senior Research Associate, University College London
• Gabriela Grigorean, Co-Ordinator, Mass Spectrometry Unit, European Institute of Oncology
• Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK
View the full programme and find out more details by contacting Andrew Gibbons on tel: +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk.
http://www.smi-online.co.uk/cancer-imaging38.asp
Imaging in Cancer Drug Development
14-15 March 2012, Copthorne Tara Hotel, London
/EINPresswire.com/ The number of patients diagnosed with cancer worldwide each year is estimated to be 12.5 million. The need for new therapeutics has never been greater. Currently, the process of drug discovery and taking a potential product through the developmental stages is a long and costly one. Taking almost 12 years and costly approximately $800 million. Pharmaceutical and research companies are looking for new ways to save costs and time. With advancements in imaging technology these companies are being given greater opportunity for translational approaches to drug development. With these opportunities companies also face challenges such as what techniques are most suited to the pathway they are trying to model? Can these models justify translation into human subjects?
Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.
Hear from industry experts on the current applications of imaging in all stages of drug design, in depth verity of imaging modalities and how they can be best applied in the drug development process. Find out how to use imaging techniques to reduce the long term cost of drug development and case studies discussions on how to best standardise imaging result from multi centre clinical trials.
Leading speakers include:
• Werner Scheuer, Research Leader Preclinical Imaging, Roche Diagnostics
• Yanping Luo, Group Leader Translational Imaging, Abbott
• Peter Eggelton, Medical Director Oncology, Merck
• Paul McSheehy, Director Oncology, Novartis
• Anthony M Giamis, Head of Radiochemistry, Abbott
• Christopher Foley, Imaging Manager, GlaxoSmithKline
• Simon Walker-Samuel, Senior Research Associate, University College London
• Gabriela Grigorean, Co-Ordinator, Mass Spectrometry Unit, European Institute of Oncology
• Francois Lassailly, In-vivo Imaging Specialist, Cancer Research UK
View the full programme and find out more details by contacting Andrew Gibbons on tel: +44 (0) 20 7827 6156 or email: agibbons@smi-online.co.uk.
http://www.smi-online.co.uk/cancer-imaging38.asp
Follow us
What people say
“We have generated many, many press clippings and improved our SEO ranking from the services that EIN Presswire provides us. Easy and simple way to upload and distribute our press releases. I would recommend their services.”
— Chris Morris, Marketing Manager of Mountz Inc.
“I have been using the EIN Press Release service for more than three years in entertainment & health care industries. Their account managers and the placement of my press releases online has been above reproach reaching mainstream journalists to help further client and brand visibility. I highly recommend this service for global notoriety and am thankful I made that first call.“
— Monica Anders PR Strategist 25 Years!
Our Partners
Press releases
- Placerville Woman Wins the Most Important Prize at Red Hawk Casino -- Her Life [23 May 2012] Marketwire
- Norilsk Nickel Announces Intention to Make All-Cash Offer for Asian Mineral Resources Limited [23 May 2012] Marketwire
- Leading Independent Steel Trader, C&F Gruenstahl Rebrands While Providing The Same Quality Services, in Energy Digital [23 May 2012] 24-7 pressrelease
© 2005-2012